ROIV
Roivant Sciences Ltd. · Healthcare
CEO Matthew Gline sold $89K of Roivant Sciences Ltd.
Sold$88,570
$4.33Price
20,455Shares
−2%Stake
What ROIV did after the filing
- The stock from Thu, Jul 28 open, $4.21
- −14.3%
- S&P 500, same days
- +1.2%
Measured over 30 trading days, to the Sep 9 close.
Traded Mon, Jul 25. Filed Wed, Jul 27, 9:08 PM ET, after the close. Returns use the Jul 28 open and the Sep 9 close. Not investment advice.